Metcela
Latest round
- Series C
Last raised
- Jun 2022
Total raised
- $28M
Investors
- 16
About Metcela
, based in Japan, is focused on developing innovative regenerative medicine therapies, particularly targeting pediatric congenital heart disease through their leading product, JRM-001.Founded in 2016 and headquartered in Tsuruoka, Japan, Metcela Inc. develops cell therapies for pediatric heart conditions. The founders, Kenichi Nogami and Takahiro Iwamiya, have aimed to carve a niche in regenerative medicine, enhancing the company’s operational focus on cellular innovation.Metcela Inc. specializes in regenerative medicine, focusing on their flagship product, JRM-001, designed to treat pediatric congenital heart disease. This therapy targets the cellular mechanisms underlying these conditions, enhancing patient quality of life by promoting cellular healing.Metcela Inc. generates revenue primarily through the commercialization of JRM-001, engaging in B2B transactions with healthcare institutions and facilities. Their revenue model includes direct sales of the therapy to hospitals and collaborations with research institutions for clinical trials.In June 2022, Metcela Inc. The company plans to utilize these funds to further develop a global ecosystem of self-regenerative medicine products. Metcela aims to expand its market reach by introducing new therapies and targeting additional geographic regions, enhancing its capabilities in regenerative healthcare.
Who invested in Metcela
16 investors across 6 rounds
See all investors in Metcela
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Metcela
Who invested in Metcela?
Metcela has 16 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Metcela raised?
Metcela has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did Metcela last raise money?
Metcela's most recent round on record is a Series C, in Jun 2022.
What does Metcela do?
, based in Japan, is focused on developing innovative regenerative medicine therapies, particularly targeting pediatric congenital heart disease through their leading product, JRM-001.
Where is Metcela headquartered?
Metcela is headquartered in Tsuruoka, Japan.
Which VCs invest in companies like Metcela?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Metcela's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Metcela? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.